Evaluation of Fowlpox-Vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1

Ranasinghe, Charani, Medveczky, Jill C., Woltring, Donna, Gao, Ke, Thomson, Scott, Coupar, Barbara E. H., Boyle, David B., Ramsay, Alistair J. and Ramshaw, Ian A. (2006) Evaluation of Fowlpox-Vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine, 24 31-32: 5881-5895. doi:10.1016/j.vaccine.2006.04.023


Author Ranasinghe, Charani
Medveczky, Jill C.
Woltring, Donna
Gao, Ke
Thomson, Scott
Coupar, Barbara E. H.
Boyle, David B.
Ramsay, Alistair J.
Ramshaw, Ian A.
Title Evaluation of Fowlpox-Vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1
Journal name Vaccine   Check publisher's open access policy
ISSN 0264-110X
0264-410X
Publication date 2006-07
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2006.04.023
Volume 24
Issue 31-32
Start page 5881
End page 5895
Total pages 15
Place of publication Oxford, U.K.
Publisher Elsevier
Language eng
Subject 110704 Cellular Immunology
11 Medical and Health Sciences
1107 Immunology
Abstract We have tested the efficacy of recombinant fowl pox (rFPV) and recombinant vaccinia virus (rVV) encoding antigens of AE clade HIV-1 in a prime-boost strategy, using both systemic and mucosal delivery routes. Of the various vaccine routes tested, intranasal/intramuscular (i.n./i.m.) AE FPV/AE VV prime-boosting generated the highest mucosal and systemic T cell responses. Peak mucosal T cell responses occurred as early as 3 days post-boost vaccination. In contrast only low systemic responses were observed at this time with the peak response occurring at day 7. Current data also revealed that, due to better uptake of the rFPV, intranasal viral priming was much more effective than intranasal rDNA priming tested previously. The i.m./i.m. prime-boost delivery also generated strong systemic but poor mucosal responses to Gag peptides. Interestingly, the oral administration of AE FPV followed by i.m. AE VV delivery elicited strong systemic responses to sub-dominant Pol 1 peptides that were absent in mice that received vaccine by other routes. Moreover, priming with AE FPV co-expressing cytokine IL-12 significantly enhanced the T cell responses to target antigens, whilst co-expression of IFNγ decreased these responses. The results also indicated that the route of inoculation and the vaccine vector combination could radically influence not only the magnitude but also the antigen specificity of the immune response generated. Further, in contrast to the generally protracted HIV rDNA/rFPV multiple delivery prime-boosting, this single rFPV prime and rVV boost approach was more flexible and generated excellent mucosal and systemic immune responses to HIV vaccine antigens.
Keyword Poxvirus
Immunodominance
Co-stimulatory molecules
Oral/intranasal rFPV delivery
Mucosal immunity
Prime-boost
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
Clinical Medical Virology Centre Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 38 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 41 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 15 Jan 2009, 13:44:10 EST by Paul Rollo on behalf of Library Corporate Services